▟ Vinebot intrinsic value, daily

← back

VTRS Viatris

pharma · valued with opus medium conviction · deep-dived 2026-10-30

HOLD
Intrinsic value$11.63
Price (at call)$19.20
Margin of safety -39.4%
vs market (rating basis) -19.1%

Shrinking generics giant; GAAP losses mask a levered cash machine, fairly to modestly overpriced today.

The story

Viatris is a scale generics and off-patent branded drug company built from the Mylan/Upjohn merger. Its moat is manufacturing scale, global distribution and a broad portfolio, not pricing power. Revenue is slowly shrinking as legacy brands erode and divestitures roll off, and GAAP losses come mostly from impairments and non-cash amortization of acquired intangibles. Underneath, it is a mature, levered cash generator whose main job is to pay down debt and return cash while stabilizing the top line through a modest pipeline.

Growth, reinvestment, risk and horizon are unchanged because the facts have not changed: there is mild erosion, capex is light and the beta is at the industry anchor. I raised the target margin from 17% to 20% (+18% relative) after reconciling with the market. My prior value was less than half the price. Reported margins are depressed by roughly 15% of sales in acquired-intangible amortization and one-off impairments, both of which run off, while sustainable cash EBIT for a scale generics player sits near 20%.

Value drivers

Revenue growth (Y1)-1.5%
Terminal growth0.5%
Forecast horizon6y
Target operating margin20.0%
Years to target margin3
Sales-to-capital1.40
Beta0.95
Failure probability5.0%
Cost of capital (WACC)7.6%
Terminal WACC7.8%

Valuation bridge

PV of explicit FCFF8.34B
PV of terminal value18.81B
Equity value13.36B
÷ shares → per share$11.63

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 14.52B -1.5% 5.8% 670.00M 0 670.00M 622.51M
2 14.36B -1.1% 12.9% 1.47B 0 1.47B 1.27B
3 14.26B -0.7% 20.0% 2.25B 0 2.25B 1.81B
4 14.21B -0.3% 20.0% 2.25B 0 2.25B 1.67B
5 14.23B 0.1% 20.0% 2.25B 10.15M 2.24B 1.55B
6 14.30B 0.5% 20.0% 2.26B 50.81M 2.21B 1.42B

Key risks

  • FDA compliance problems (e.g., the Indore facility) disrupting supply and US generics revenue
  • Faster price erosion in US generics and in legacy brands like Lipitor and Norvasc in China and emerging markets
  • About $13B of net debt magnifies any cash-flow shortfall, and more impairments may point to overpaid assets

Catalysts

  • Continued deleveraging and buybacks shrinking the share count
  • Pipeline approvals (e.g., novel and complex injectables) that halt revenue decline

History

DatePriceIntrinsicMoSRating
2026-10-30$19.20 $11.63 -39.4% HOLD
2026-09-28$17.83 $7.98 -55.3% SELL
2026-08-25$16.54 $0.00 -100.0% STRONG SELL
2026-07-23$17.01 $0.90 -94.7% STRONG SELL
2026-06-23$15.75 $0.94 -94.1% STRONG SELL